Home > Press > Copernicus Receives Milestone Payment from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic Fib
Copernicus Therapeutics, Inc. announced today that it received a milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation. This milestone payment is part of a research, development, and commercialization agreement between CFFT and Copernicus to develop gene therapy to treat cystic fibrosis.
Copernicus Receives Milestone Payment from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic Fib
Cleveland, OH | Posted on December 11th, 2007
Copernicus earned the milestone payment by demonstrating a significant improvement in the level of CFTR gene activity in an animal model. This increased improvement in the level and duration of CFTR gene activity represents an important step in the path to developing a clinically relevant therapy.
Copernicus' unique, non-viral nanoparticle formulation is intended to deliver a normal copy of the CF gene to the affected lung cells of CF patients, and may provide a therapy that treats the root cause of CF regardless of the specific mutations resulting in CF. Copernicus' first clinical trial, supported by CFFT, demonstrated the desired safety profile and encouraging biological changes were observed.
Cystic fibrosis is a life threatening genetic disease that affects approximately 30,000 children and adults in the United States. People with CF develop serious lung infections and digestive complications. About 10 million Americans are unknowing carriers of a defective CF gene.
"We have had a productive relationship for a number of years with CFFT and we share the common goal of providing a safe and effective therapeutic for people with CF," said Robert C. Moen, M.D., Ph.D., president and CEO of Copernicus. "We look forward to working with CFFT in meeting the critical need for an effective gene-based therapy for the lung manifestations of CF."
"We are encouraged by the promise of Copernicus' technology," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. "Gene-based therapies offer hope for potentially lifesaving treatments that can be applied to all patients with CF, regardless of the specific type of gene mutation."
About Copernicus Therapeutics, Inc.
Copernicus Therapeutics, Inc., a privately held biotechnology company, is dedicated to delivering the promise of nucleic acid therapeutics. The Copernicus multi-component delivery platform can be used to develop nucleic acid therapies for numerous human diseases. The same technology that is being tested for its ability to deliver the CF gene to the lung of CF patients can be applied to treating serious disorders of the brain, such as Parkinsonís disease, as well as for treating a variety of blinding disorders. Additionally, this lung delivery technology may be utilized for RNAi-based therapeutics to treat lung infections caused by influenza A, bird flu, and other respiratory viruses. Additional information about Copernicus is available at http://www.cgsys.com .
The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and supports and accredits a nationwide network of 115 CF care centers, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.
For more information, please click here
Copernicus Therapeutics, Inc.
Robert C. Moen, M.D., Ph.D.
President & CEO
Mark J. Cooper, M.D.
Sr. V.P. of Science and Medical Affairs
Cystic Fibrosis Foundation
Director of Media Relations
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nano Labs Shareholder Update March 8th, 2014
MANA Research Highlight: Smart nanofibers to treat kidney failure March 6th, 2014
Harris & Harris Group, Inc. Establishes and Invests $350,001 in ProMuc, Inc. March 6th, 2014
First Look at How Individual Staphylococcus Cells Adhere to Nanostructures Could Lead to New Ways to Thwart Infections: Berkeley Lab-led research could guide the development of bacteria-resistant materials March 5th, 2014
Nano Labs Shareholder Update March 8th, 2014
Squeezing light into metals: University of Utah engineers control conductivity with inkjet printer March 7th, 2014
Up-Converted Radio: The way to treat radio waves in a noisy environment is to turn them into visible light March 7th, 2014
Carbodeon NanoDiamonds PTFE Coating doubles surface durability and reduces friction by up to 66 percent: New surface coating enables cost-effective CO2 and fuel reductions in machinery March 6th, 2014